Neuronetics (NASDAQ:STIM) CEO Keith Sullivan Sells 33,847 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith Sullivan sold 33,847 shares of the firm’s stock in a transaction that occurred on Thursday, February 12th. The shares were sold at an average price of $1.65, for a total value of $55,847.55. Following the sale, the chief executive officer owned 1,533,165 shares of the company’s stock, valued at approximately $2,529,722.25. This trade represents a 2.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Neuronetics Stock Performance

Neuronetics stock opened at $1.38 on Thursday. Neuronetics, Inc. has a 52 week low of $1.25 and a 52 week high of $5.92. The company has a current ratio of 2.24, a quick ratio of 2.09 and a debt-to-equity ratio of 2.09. The stock has a market cap of $94.52 million, a P/E ratio of -1.68 and a beta of 0.79. The stock has a 50 day moving average of $1.69 and a 200-day moving average of $2.38.

Analysts Set New Price Targets

Several equities analysts have recently commented on STIM shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Neuronetics in a research report on Thursday, January 22nd. Wall Street Zen raised Neuronetics from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Neuronetics has a consensus rating of “Hold” and an average target price of $7.00.

Institutional Trading of Neuronetics

Several hedge funds have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey bought a new position in Neuronetics during the 2nd quarter worth $34,000. Raymond James Financial Inc. bought a new position in shares of Neuronetics during the second quarter worth about $37,000. Presidio Capital Management LLC acquired a new stake in shares of Neuronetics in the 3rd quarter worth about $32,000. Intrua Financial LLC bought a new stake in Neuronetics in the 3rd quarter valued at about $33,000. Finally, Sherbrooke Park Advisers LLC bought a new stake in Neuronetics in the 3rd quarter valued at about $33,000. Institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.